Taton G
Department of Gastrointestinal Surgery, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Belgium.
Acta Chir Belg. 1996 Apr;96(2):59-61.
The primary mode of management of gastric carcinoma is surgical resection with 5-year survival rate following curative resection of about 30 to 40%. This article reviews the results of randomized clinical trials including adjuvant chemotherapy, radiation treatment and chemoimmunotherapy after curative surgical resection. Randomized trials done to date largely do not support the use of adjuvant chemotherapy in resected gastric cancer. Mitomycin C or FAM association have demonstrated the best efficiency with increase of median survival in treated patients. Mitomycin C demonstrated a significant advantage by reduction of the incidence of hematogenous metastases. Encouraging perspectives come from the association between chemotherapy and biochemical modulators.
胃癌的主要治疗方式是手术切除，根治性切除后的5年生存率约为30%至40%。本文回顾了根治性手术切除后辅助化疗、放疗和化学免疫治疗的随机临床试验结果。迄今为止进行的随机试验大多不支持在切除的胃癌中使用辅助化疗。丝裂霉素C或FAM联合方案已显示出最佳疗效，可提高治疗患者的中位生存期。丝裂霉素C通过降低血行转移的发生率显示出显著优势。化疗与生化调节剂联合使用带来了令人鼓舞的前景。
